Urban K, Mehrmal S, Uppal P, Giesey RL, Delost GR. The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990–2017. JAAD Int. 2021;2:98–108.

Article  PubMed  PubMed Central  Google Scholar 

Cancer Today [Internet]. [cited 2024 Feb 26]. Available from: https://gco.iarc.who.int/today/.

Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer Oxf Engl. 1990;2023(192): 113254.

Google Scholar 

Brougham NDLS, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106:811–5.

Article  PubMed  Google Scholar 

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. Treatment-update 2023. Eur J Cancer Oxf Engl 1990. 2023;193:113252.

CAS  Google Scholar 

Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, et al. French updated recommendations in Stage I to III melanoma treatment and management. J Eur Acad Dermatol Venereol. 2017;31:594–602.

Article  CAS  PubMed  Google Scholar 

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment—update 2022. Eur J Cancer Oxf Engl 1990. 2022;170:256–84.

Google Scholar 

El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens—part D: radiation. Lancet Oncol. 2009;10:751–2.

Article  PubMed  Google Scholar 

Krensel M, Schäfer I, Augustin M. Cost-of-illness of melanoma in Europe—a modelling approach. J Eur Acad Dermatol Venereol JEADV. 2019;33(Suppl 2):34–45.

Article  PubMed  Google Scholar 

Guy GPJ, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the US, 2002–2006 and 2007–2011. Am J Prev Med. 2015;48:183–7.

Article  PubMed  Google Scholar 

Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465–72.

Article  PubMed  PubMed Central  Google Scholar 

Krensel M, Schäfer I, Augustin M. Modelling first-year cost-of-illness of melanoma attributable to sunbed use in Europe. J Eur Acad Dermatol Venereol JEADV. 2019;33(Suppl 2):46–56.

Article  PubMed  Google Scholar 

Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37.

Article  PubMed  PubMed Central  Google Scholar 

Krensel M, Schäfer I, Augustin M. Cost-of-illness of melanoma in Europe—a systematic review of the published literature. J Eur Acad Dermatol Venereol JEADV. 2019;33:504–10.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. Statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71.

Google Scholar 

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.

Google Scholar 

Schirr-Bonnans S, Costa N, Derumeaux-Burel H, Bos J, Lepage B, Garnault V, et al. Cost of diabetic eye, renal and foot complications: a methodological review. Eur J Health Econ. 2017;18:293–312.

Article  PubMed  Google Scholar 

Tripathi R, Knusel KD, Ezaldein HH, Bordeaux JS, Scott JF. Characteristics of patients hospitalized for cutaneous squamous cell carcinoma. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2020;46:742–6.

CAS  Google Scholar 

Annemans L. Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations. New York: Academia Press; 2008.

Google Scholar 

Gordon LG, Leung W, Johns R, McNoe B, Lindsay D, Merollini KMD, et al. Estimated healthcare costs of melanoma and keratinocyte skin cancers in Australia and Aotearoa New Zealand in 2021. Int J Environ Res Public Health. 2022;19:3178.

Article  PubMed  PubMed Central  Google Scholar 

Doran CM, Ling R, Byrnes J, Crane M, Searles A, Perez D, et al. Estimating the economic costs of skin cancer in New South Wales, Australia. BMC Public Health. 2015;15:952.

Article  PubMed  PubMed Central  Google Scholar 

Gordon LG, Elliott TM, Wright CY, Deghaye N, Visser W. Modelling the healthcare costs of skin cancer in South Africa. BMC Health Serv Res. 2016;16:113. https://doi.org/10.1186/s12913-016-1364-z.

Rowell D, Gordon LG, Olsen CM, Whiteman DC. A reconstruction of a medical history from administrative data: with an application to the cost of skin cancer. Health Econ Rev. 2015;5:4. https://doi.org/10.1186/s13561-015-0042-x.

Vallejo-Torres L, Morris S, Kinge JM, Poirier V, Verne J. Measuring current and future cost of skin cancer in England. J Public Health Oxf Engl. 2014;36:140–8.

Article  CAS  Google Scholar 

Bentzen J, Kjellberg J, Thorgaard C, Engholm G, Phillip A, Storm HH. Costs of illness for melanoma and nonmelanoma skin cancer in Denmark. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2013;22:569–76.

Article  Google Scholar 

Mofidi A, Tompa E, Spencer J, Kalcevich C, Peters CE, Kim J, et al. The economic burden of occupational non-melanoma skin cancer due to solar radiation. J Occup Environ Hyg. 2018;15:481–91.

Article  PubMed  Google Scholar 

Pil L, Hoorens I, Vossaert K, Kruse V, Tromme I, Speybroeck N, et al. Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. Prev Med. 2016;93:177–82.

Article  PubMed  Google Scholar 

Buja A, Sartor G, Scioni M, Vecchiato A, Bolzan M, Rebba V, et al. Estimation of direct melanoma-related costs by disease stage and by phase of diagnosis and treatment according to clinical guidelines. Acta Derm Venereol. 2018;98:218–24.

Article  PubMed  Google Scholar 

Buja A, Rugge M, De Luca G, Zorzi M, De Toni C, Cozzolino C, et al. Malignant melanoma: direct costs by clinical and pathological profile. Dermatol Ther. 2022;12:1157–65.

Article  Google Scholar 

da Veiga CRP, da Veiga CP, Souza A, Wainstein AJA, de Melo AC, Drummond-Lage AP. Cutaneous melanoma: cost of illness under Brazilian health system perspectives. BMC Health Serv Res. 2021;21:284.

Article  PubMed  PubMed Central  Google Scholar 

Reyes C, DaCosta BS, Linke R, Satram-Hoang S, Teitelbaum AH. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. Melanoma Res. 2013;23:159–66.

Article  PubMed  Google Scholar 

Buja A, Cozzolino C, Zanovello A, Geppini R, Miatton A, Zorzi M, et al. Cost items in melanoma patients by clinical characteristics and time from diagnosis. Front Oncol. 2023;13:1234931.

Article  PubMed  PubMed Central  Google Scholar 

Bateni SB, Nguyen P, Eskander A, Seung SJ, Mittmann N, Jalink M, et al. Changes in health care costs, survival, and time toxicity in the era of immunotherapy and targeted systemic therapy for melanoma. JAMA Dermatol. 2023;159:1195–204.

Article  PubMed  PubMed Central  Google Scholar 

Crealey GE, Hackett C, Harkin K, Heckmann P, Kelleher F, Lyng Á, et al. Melanoma-related costs by disease stage and phase of management in Ireland. J Public Health Oxf Engl. 2023;45:714–22.

Article  Google Scholar 

Bencina G, Buljan M, Situm M, Stevanovic R, Benkovic V. Health and economic burden of skin melanoma in Croatia—cost-of-illness study. ACTA Dermatovenerol Croat. 2017;25:1–7.

PubMed  Google Scholar 

Ignateva V, Derkach EV, Omelyanovsky V, Avxentyeva M. Economic burden of melanoma in Russia. Value Health. 2012;15:A417.

Article  Google Scholar 

Watts C, Cust A, Menzies S, Coates E, Mann G, Morton R. Specialized surveillance for individuals at high risk for melanoma a cost analysis of a high-risk clinic. JAMA Dermatol. 2015;151:178–86.

Article  PubMed  Google Scholar 

Look Hong NJ, Cheng SY, Wright FC, Petrella TM, Earle CC, Mittmann N. Resource utilization and disaggregated cost analysis for initial treatment of melanoma. J Cancer Policy. 2018;16:63–9.

Article  Google Scholar 

Kapaki V, Kotsopoulos N, Constantopoulos A, Mathioudakis K, Souliotis K. The economic burden of cutaneous malignant melanoma in the Greek outpatient setting during the 3-year period, 2017–2019. Arch Hell Med. 2023;40:245–53.

Google Scholar 

McCarron CE, Zaric GS, Ernst DS. Costs and survival of patients with metastatic melanoma: evidence from the Ontario Cancer Registry and administrative databases. J Popul Ther Clin Pharmacol. 2014;21: e144.

Google Scholar 

de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KKW, Cheung WY, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16:809.

Article  PubMed  PubMed Central  Google Scholar 

Chang C, Schabert V, Munakata J, Donga P, Abhyankar S, Reyes C, et al. Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Res. 2015;25:312–20.

Article  PubMed  Google Scholar 

Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin. 2015;31:1561–72.

Article  PubMed  Google Scholar 

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, et al. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in the Netherlands. Anticancer Drugs. 2018;29:579–88.

Article  CAS  PubMed